•  MOXATAG 775 mg once-daily provided clinically demonstrated efficacy in the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes (S. pyogenes)1
• In the per-protocol population, MOXATAG achieved bacterial eradication rates of 85.0% vs 83.4% with penicillin VK: rate difference 95% CI(%): 1.6 (-5.1, 8.2)1
Timed releases of amoxicillin ensure adequate drug levels to treat S. pyogenes with just 1 daily dose for 10 days.1
*Eligible patients save up to $80.
Patients may pay as little as $10* for their prescription with a MOXATAG Pharmacy Savings Card.
*MOXATAG is indicated for the treatment of tonsillitis and/or pharyngitis secondary to S. pyogenes in adult and pediatric patients 12 years of age or older.1
†Amoxicillin approved adult dosing regimens for ear, nose, and throat infections: 500 mg BID or 250 mg TID for mild to moderate infections; 875 mg BID or 500 mg TID for severe infections. It is recommended that there be at least 10 days treatment for any infection caused by Streptococcus pyogenes to prevent the occurrence of acute rheumatic fever.3
MOXATAG tablets should be taken within 1 hour of finishing a meal for 10 days1
The full 10-day course of therapy should be completed for effective treatment of tonsillitis and/or pharyngitis secondary to S. pyogenes1
Do not chew or crush tablet1
References: 1. MOXATAG [package insert]. Berwyn, PA: Vernalis Therapeutics, Inc; 2016. 2. Orange Book: Approved drug products with therapeutic equivalence evaluations. US Food and Drug Administration website. http://www.accessdata.fda.gov/scripts/cder/ob/. Accessed July 8, 2016. 3. Amoxicillin tablets USP [package insert]. Sellersville, PA: Teva Pharmaceuticals USA; 2011.